Zandi Hudspeth
Payments from drug & device makers
Across 257 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$951
- Novo Nordisk$766
- Lilly USA, LLC$503
- Amgen$342
- GSK$237
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$202
- plus $902 from 19 others
What the payments were for
- Food & beverage$3,903100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 72 | $951 |
| Novo Nordisk | 52 | $766 |
| Lilly USA, LLC | 36 | $503 |
| Amgen | 25 | $342 |
| GSK | 12 | $237 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $202 |
| Amarin Pharma, Inc. | 7 | $150 |
| Esperion Therapeutics, Inc. | 7 | $101 |
| Boston Scientific | 1 | $93 |
| Johnson & Johnson | 4 | $72 |
| Bayer | 4 | $72 |
| Pfizer | 3 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Supernus Pharmaceuticals, Inc. | 2 | $45 |
| Exact Sciences | 3 | $44 |
| AstraZeneca | 2 | $35 |
| Lundbeck LLC | 2 | $32 |
| Tris Pharma Inc | 2 | $31 |
| Dexcom, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Renalytix AI, Inc. | 1 | $23 |
| Organon | 1 | $16 |
| Global Blood Therapeutics, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
How this compares
$3,903 in reported general payments places this provider in the 85th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 56 | $81,807 |
| OzempicSemaglutide | 38 | $42,936 |
| JardianceEmpagliflozin | 29 | $28,981 |
| EliquisApixaban | 46 | $28,446 |
| JanuviaSitagliptin Phosphate | 13 | $19,917 |
| TrulicityDulaglutide | 17 | $17,067 |
| VascepaIcosapent Ethyl | 37 | $15,499 |
| NexlizetBempedoic Acid/Ezetimibe | 21 | $10,335 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,538 |
| LinzessLinaclotide | 11 | $8,803 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $7,849 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,704 |
| TrulancePlecanatide | 14 | $6,930 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $6,246 |
| MyrbetriqMirabegron | 12 | $5,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $503 | $98,87473 claims |
| Novo NordiskOzempic | $766 | $42,93638 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $14 | $35,22742 claims |
| PfizerEliquis | $51 | $28,44646 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $35 | $12,76126 claims |
| Esperion Therapeutics, Inc.Nexlizet | $101 | $10,33521 claims |
| AbbVieLinzess | $951 | $8,80311 claims |
| GSKBreo Ellipta | $237 | $7,70419 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $202 | $6,93014 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $5,19912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,610 family providers in Louisiana.
Other family in Amite
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.